More on BIVI
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.13 |
|
|||
| Open | $1.13 | ||||
| 52 Wk High | $0.40 | ||||
| 52 Wk Low | $0.17 | ||||
| Day High | $1.22 | ||||
| Day Low | $1.12 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 275,574 | ||||
- BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
- New to The Street Show 775 Premieres Tonight on Bloomberg Television Across the United States, Latin America, MENA and Southeast Asia, Featuring American Fusion, HPB, T-REX Acquisition Corp. and SyncM
- Form DEF 14A BIOVIE INC. For: Sep 28
- New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
- New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
- Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
- BioVie to host investor webinar on Phase 2 Long COVID trial data
- Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results
- BioVie reports Phase 2 Long COVID drug trial results in subgroups
- BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Entities mentioned with BIVI
- FDA | View Related Stories »
- Dividend | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- ThinkEquity | View Related Stories »
- S1 | View Related Stories »
- Show More...
